News on diagnostics for respiratory pathogens, including influenza, coronavirus, and more.
The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.
The test, which is in development using perspiration as a sample, has shown promising performance in a preliminary study.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
